# Topical Everolimus in Patients With Tuberous Sclerosis Complex

> **NCT02860494** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Hospices Civils de Lyon**

## Conditions studied

- Facial Angiofibromas

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02860494
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2023-12
- **Final completion:** 2024-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Pharmaceutical and financial difficulties
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02860494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02860494, "Topical Everolimus in Patients With Tuberous Sclerosis Complex". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02860494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*